Instil Bio, Inc (TIL) - Forward P/S Multiple

Public company logo of Instil Bio (TIL)

Instil Bio, Inc. (TIL) is strengthening its image as an innovator in cellular oncology therapy, as confirmed by the current GURU.Markets platform chart: the forward P/S indicator demonstrates that the value of expresses the metric level. Despite the logistics risks associated with live cells during periods of global strife, operating within US scientific clusters ensures R&D stability and a neutral geopolitical backdrop.

Instil Bio - TIL Market Cap to Future Revenue Ratio (period 07/04/2022 - 11/13/2026)

TIL (Instil Bio Inc): analytical breakdowns and indicator data

- stock price and consensus target price:
Stock Quotes Instil Bio|TIL - Fair Value Consensus
- market capitalization indicators:
Market Capitalization Instil Bio Inc|TIL - Full Takeover Company Value
- issuer book value statistics:
Book Value per Share Instil Bio|TIL - Total Stockholders' Equity|Market Value to Book Value Ratio instilbio.com|TIL - Total Business Assets
- debt and liquidity details:
Total Debt to Capital Instil Bio, Inc.|TIL - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio Instil Bio, Inc.|TIL - Aggregate Debt Obligations|Debt to Book Value Instil Bio Inc|TIL - Amount of Long-Term Liabilities|Company Short-Term Debts Instil Bio|Quick Ratio instilbio.com
- financial results and valuation multiples details:
TIL - Company Net Income|Expected Profit Instil Bio, Inc.|TIL - Company Value to Net Income|Forward P/E Multiple Instil Bio, Inc|TIL - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Instil Bio Inc|TIL - Profit before deduction of interest, taxes, depreciation and amortization|Net earnings per share for the last 12 months Instil Bio|TIL - Net earnings per one share for the last twelve months|Quarterly EPS earnings growth instilbio.com|TIL - Expected net earnings per share growth this year|Net earnings per share growth forecast for next year Instil Bio, Inc.
- revenue and sales details:
TIL - Company Sales Volume|Company Projected Revenue Instil Bio|TIL - Price-to-Revenue Coefficient|Forward Price-to-Revenue Multiple Instil Bio Inc
Summary company analysis:Instil Bio (TIL)
Product sample of instilbio.com

To minimize risks when valuing Instil Bio, Inc. (TIL), it is essential to separate market noise from genuine fundamental shifts. By analyzing the forward price-to-sales ratio, an investor observes the result of discounting future flows, where market capitalization is weighed against expected revenue; for Instil Bio, Inc. (TIL), this balance is critical, as the high cost of the R&D core and the aggressive poaching of scarce biotechnologists directly determine future revenue potential.

Competing companies

Legend Biotech Corporation - Forward Price-to-Revenue Multiple|Forward Price to Sales SANA|Autolus Pharma - Forward P/S Multiple|Projected Price to Revenue Allogene Corp (ALLO)|RNAC: Forward P/S Multiple|Market Cap to Future Revenue Ratio Cellectis (CLLS)|Price-to-Projected Revenue Ratio Caribou Biosciences, Inc.|Market Cap to Projected Revenue GNTA (Genenta)|Forward P/S Multiple IPSC|JSPR - Market Cap to Future Revenue Ratio|Senti Biosciences - Forward Price-to-Revenue Multiple|Forward Price to Sales ADAP|CERO: Forward Price-to-Revenue Multiple|Alaunos Therapeutics - Price to Expected Revenue Ratio|ACHL: Forward P/S Multiple|CARGO Therapeutics, Inc - Forward Price to Sales|PSTX (Poseida Therapeutics) - Forward P/S Multiple|Market Cap to Future Revenue Ratio 2seventybio.com TSVT|Price-to-Projected Revenue Ratio Gracell Biotechnologies Inc. (GRCL)